Research Article

Interleukin-16 Gene Polymorphisms Are Considerable Host Genetic Factors for Patients’ Susceptibility to Chronic Hepatitis B Infection

Sara Romani,1,2 Seyed Masoud Hosseini,2 Seyed Reza Mohebbi,1 Shabnam Kazemian,3 Shaghayegh Derakhshani,1 Mahsa Khanyaghma,1 Pedram Azimzadeh,1,3 Afsaneh Sharifian,1 and Mohammad Reza Zali1

1 Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Microbiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran
3 Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Pedram Azimzadeh; azimzadeh.pedram@gmail.com

Received 21 July 2014; Accepted 13 November 2014; Published 26 November 2014

Academic Editor: Piero Luigi Almasio

Copyright © 2014 Sara Romani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Host genetic background is known as an important factor in patients’ susceptibility to infectious diseases such as viral hepatitis. The aim of this study was to determine the effect of genetic polymorphisms of interleukin-16 (IL-16) cytokine on susceptibility of hepatitis B virus (HBV) infected patients to develop chronic HBV infection. Genotyping was conducted using PCR followed by enzymatic digestion and RFLP (restriction fragment length polymorphism) analysis. We genotyped three single nucleotide polymorphisms (SNPs) in the \( \text{Il-16} \) gene (rs11556218 T>G, rs4778889 T>C, and rs4072111 C>T) to test for relationship between variation at these loci and patients’ susceptibility to chronic HBV infection. Allele frequency of \( \text{Il-16} \) gene rs4072111 and rs11556218 was significantly different between chronic HBV patients and healthy blood donors. Genotype frequency of rs4778889 polymorphism of \( \text{Il-16} \) gene was significantly different when chronic HBV patients and HBV clearance subjects were compared. Our results showed that \( \text{Il-16} \) gene polymorphisms are considerable host genetic factors when we chase biomarkers for prognosis of HBV infected patients.

1. Background and Objectives

More than 350 million individuals around the world are infected with hepatitis B virus. The diagnosis of chronic infection is made by a combination of serology, viral, and biochemical markers [1]. Prevalence of anti-HBc and HBsAg in the United States at 2006 is estimated to be 4.7% and 0.27%, respectively [2].

Iran is located on intermediate endemic region for hepatitis B infection and prevalence of HBsAg positivity among general adult population in about 3 to 10 percent in different regions [3]. World Health Organization (WHO) and Center for Disease Control and Prevention (CDC) reported that prevalence of chronic hepatitis B infection in Iran ranges between 2 and 7 percent [4].

Occult HBV infection is reported among 7 to 13 percent of anti-HBc positive and/or anti-HBs positive subjects, but this type of viral hepatitis is seen in 0 to 17 percent of healthy blood donors. When we investigate the susceptibility factors for HBV clearance this phenomenon could have confounder effect. So HBV-DNA PCR test must be performed for all study subjects to obviate this issue [5].

Interleukin-16 (IL-16) is a multifunctional cytokine with the role of immune response synchronization and direction [6]. The mature secreted form of this protein acts as a ligand for CD4+ cells and this ligand-receptor binding leads to activation of a key intracellular pathway that regulates T cell proliferation [7]. The major IL-16 related functional proteins are STAT6, interleukin-4 (IL-4), and tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)) [8].
Some current efforts to prevent the populations from the infectious diseases such as viral hepatitis have focused on finding powerful genetic susceptibility biomarkers [9]. In recent years few polymorphism markers have been found in association with viral hepatitis. SNPs located in HLA-DPA1 and HLA-DPB1 genes were identified as protective factors for chronic hepatitis B infection [10] and SNPs of IL28B gene were significantly related to spontaneous clearance of hepatitis C infection [11].

HBV clearance is in connection with powerful CD4+ T cells and Il-16 plays a critical role in T cell regulation [12]. Due to this, phenomenon variations occurring in Il-16 gene sequence could affect its function and cause deregulation in immune response against viral hepatitis [13].

Present study was designed to investigate the relationship between three SNPs of Il-16 gene and patients’ susceptibility to chronic hepatitis B infection and to determine the effect of Il-16 gene polymorphisms on development of chronic HBV infection.

2. Methods

2.1. Study Population. Seven hundred and forty-four individuals were enrolled in the genotyping procedure including 245 chronic HBV patients, 105 HBV clearance subjects, and 394 healthy controls. Inclusion criteria for chronic hepatitis B patients group were HBsAg positive test for at least 6 months and HBV infection was confirmed by detection of serum HBV DNA using PCR method. The patients with these characteristics were excluded from study: HCV or HIV co-infection and history of autoimmune diseases. HBV clearance group consisted of individuals with anti-HBc positive and HBs-antigen negative tests. All healthy control subjects were anti-HBc, HBs-antigen, and HBV-DNA PCR negative and have not met these criteria, any history of hepatitis or liver dysfunction, autoimmune diseases, and HCV or HIV.

2.2. Single Nucleotide Polymorphisms. According to literature review and basic information about the Il-16 cytokine, we selected three SNPs in the Il-16 gene sequence including rs11556218 T>G, rs4778889 T>C, and rs4072111 C>T. The minor allele frequency (MAF) of all three selected SNPs was greater than 0.05 according to previous studies.

2.3. Genomic DNA Purification and Genotyping. Blood samples were collected from all study subjects in EDTA coated tubes. Genomic DNA was extracted from whole blood using standard phenol chloroform method as previously described by Sambrook [14]. Genotype determination for three selected SNPs was performed by PCR-RFLP method as previously described by Gao et al. [15] Primer sequences and RFLP material are presented in Table 1. In brief pure PCR products were obtained using specific primer pairs (Bioneer, South Korea) for each SNP; and enzymatic digestion for each one was performed using specific restriction endonucleases (Fermentas, Latvia). Digested DNA was analyzed on 3% low electroendosmosis agarose gel (Agarose LE, Roche, Germany).

2.4. Direct Sequencing. To confirm the results of RFLP analysis we performed direct sequencing using chain termination method and 3130xl genetic analyzer instrument (Applied Biosystems, USA) for 5% of our samples as duplicate genotyping.

2.5. Statistical Analysis. Statistical analyses were carried out using IBM SPSS software version 20 (IBM SPSS Statistics 20; SPSS, Chicago, IL). P values less than 0.05 were considered as significant. To compare three included groups (HBV cases, HBV clearance, and healthy controls) for their genotype and allele status we performed Chi square test and to consider the simultaneous effect of genotype and allele along with gender and age (as probable confounder variables) we conducted a logistic regression test. To compare the mean age between three studied groups we used one-way ANNOVA.

3. Results

Among 245 chronic HBV patients 157 (64.1%) individuals were male and 88 (35.9%) were female and from 394 healthy controls 205 (52%) were male and 189 (48%) were female; so our third group (HBV clearance) consisted of 64 male and 41 female, total 105 subjects. Mean age in chronic HBV group was 49.15 ± 15.50 years, in healthy control group was 45.26 ± 14.42 years, and in HBV clearance group was 42.2 ± 14.96 years; there was a significant difference between three groups according to age and gender status (P value < 0.05). In order
Table 2: Allele and genotype frequency of three SNPs among chronic HBV patients versus healthy control subjects.

| SNP        | Variable | Healthy control (n = 394) n (%) | HBV patient (n = 245) n (%) | Adjusted* OR (95% CI), Pvalue |
|------------|----------|---------------------------------|-----------------------------|-----------------------------|
| rs4072111  | Genotypes |                                 |                             |                             |
|            | CC       | 316 (80.2)                      | 181 (73.9)                  | 1.00 (reference)            |
|            | CT       | 74 (18.8)                       | 58 (23.7)                   | 1.391 (0.937–2.066), 0.102  |
|            | TT       | 4 (1.0)                         | 6 (2.4)                     | 2.929 (0.787–10.894), 0.109  |
| Alleles    | C        | 706 (89.6)                      | 420 (85.7)                  | 1.00 (reference)            |
|            | T        | 82 (10.4)                       | 70 (14.3)                   | 1.471 (1.039–2.081), 0.029  |
| rs11556218 | Genotypes |                                 |                             |                             |
|            | TT       | 124 (31.5)                      | 43 (17.6)                   | 1.00 (reference)            |
|            | TG       | 215 (54.6)                      | 147 (60)                    | 2.028 (1.344–3.061), 0.001  |
|            | GG       | 55 (14)                         | 55 (22.4)                   | 2.894 (1.722–4.864), 0.000  |
| Alleles    | T        | 463 (58.8)                      | 233 (47.6)                  | 1.00 (reference)            |
|            | G        | 325 (41.2)                      | 257 (52.4)                  | 1.574 (1.250–1.982), 0.000  |
| rs4778889  | Genotypes |                                 |                             |                             |
|            | TT       | 264 (67)                        | 156 (63.7)                  | 1.00 (reference)            |
|            | TC       | 111 (28.2)                      | 84 (34.3)                   | 1.303 (0.916–1.853), 0.140  |
|            | CC       | 19 (4.8)                        | 5 (2)                       | 0.439 (0.159–1.216), 0.113  |
| Alleles    | T        | 639 (81.1)                      | 396 (80.8)                  | 1.00 (reference)            |
|            | C        | 149 (18.9)                      | 94 (19.2)                   | 1.027 (0.767–1.375), 0.860  |

* Adjusted for confounder variables: age and gender.

All subjects were genotyped for three SNPs of Il-16 gene sequence. When comparing chronic HBV patients with healthy blood donors, we found a significant association between T allele of rs4072111 polymorphism and higher risk of chronic disease development (P value: 0.029, OR: 1.471, and 95% CI: 1.039–2.081). Frequency of TG and GG genotypes and G allele distribution in rs11556218 polymorphism were also significantly different between two study groups, but our results showed no statistically significant difference between allele and genotype frequency of rs4778889 polymorphism between chronic HBV patients and healthy control group. These data are summarized in Table 2. Despite these findings, we found a statistically significant relationship between the rs4778889 CC genotype (rare genotype) and three times higher risk for chronic HBV infection, when we compare chronic HBV and HBV clearance groups (P value: 0.035, OR: 3.723, and 95% CI: 1.100–12.602). Summary of genotyping data of chronic HBV and HBV clearance groups is shown in Table 3.

4. Discussion

The mechanisms involved in the patients’ susceptibility to chronic hepatitis B infection are not well understood. Clearance or pathogenesis of HBV infection is expected to be multifactorial affected by environmental, viral factors, and host genetic variations. The products of many human genes and their downstream effectors influence host defense against HBV infection and person to person differences in susceptibility to chronic hepatitis disease.

Precursor of human Il-16 protein contains 631 amino acids and is constitutively synthesized in unstimulated T cells. This peptide goes through proteolytic processing that results in a 121-amino acid bioactive molecule [5]. Almost all 121 amino acids of this peptide are involved in PDZ domains and this phenomenon makes it a unique structure [16]. Il-16 is secreted by several types of cells and its association with recruitment of CD4+ immune cells to location of inflammation. Involvement of Il-16 in pathogenesis of viral hepatitis is in connection with its receptor (CD4) [17]. Il-16 is produced by a variety of immune cells in addition to CD4+ and CD8+ T cells [18]. Biological activities of Il-16 cytokine are chemotaxis of CD4+ cells, upregulation of CD25 protein, and secretion of interleukin-1β (Il-1β), interleukin-4 (Il-4), and tumor necrosis factor-α (TNF-α). On the other hand, activation of STAT6 protein is a common function in CD4+ cells, and STAT6 together with Il-4 are involved in T cell mediated hepatitis. This pathway of events is consistent with the fact that immune responses related to T lymphocytes are important in viral hepatitis [19, 20].

There is limited data about the association of SNPs in the Il-16 gene sequence and risk of chronic hepatitis B infection, whereas the role of cellular immunity in dealing with hepatitis HBV infection is clear and on the other hand CD4 (receptor of Il-16) is involved in this process [21, 22]. So it might be considered that Il-16 plays a role in immune response against HBV infection.
Table 3: Allele and genotype frequency of three SNPs among chronic HBV patients versus HBV clearance subjects.

| SNP     | Variable | HBV clearance (n = 105) n (%) | HBV patient (n = 245) n (%) | Adjusted* OR (95% CI), P<sub>value</sub> |
|---------|----------|-------------------------------|----------------------------|----------------------------------------|
|         | Genotypes |                               |                            |                                        |
|         | CC        | 86 (81.9)                     | 181 (73.9)                 | 1.00 (reference)                       |
|         | CT        | 17 (16.2)                     | 58 (23.7)                  | 0.577 (0.307–1.082), 0.086            |
| rs4072111 | TT        | 2 (1.9)                       | 6 (2.4)                    | 0.814 (0.142–4.672), 0.817            |
| Alleles | C         | 189 (89.6)                    | 420 (85.7)                 | 1.00 (reference)                       |
|         | T         | 21 (10.4)                     | 70 (14.3)                  | 0.651 (0.378–1.121), 0.122            |
|         | Genotypes |                               |                            |                                        |
|         | TT        | 16 (15.2)                     | 43 (17.6)                  | 1.00 (reference)                       |
| rs11556218 | TG       | 63 (60)                       | 147 (60)                   | 1.118 (0.567–2.203), 0.748            |
| Alleles | T         | 95 (45.2)                     | 233 (47.6)                 | 1.00 (reference)                       |
|         | G         | 115 (54.8)                    | 257 (52.4)                 | 1.109 (0.788–1.561), 0.509            |
|         | Genotypes |                               |                            |                                        |
|         | TT        | 68 (64.8)                     | 156 (63.7)                 | 1.00 (reference)                       |
| rs4778889 | TC        | 29 (27.6)                     | 84 (34.3)                  | 0.785 (0.459–1.342), 0.376            |
| Alleles | T         | 165 (78.6)                    | 396 (80.8)                 | 1.00 (reference)                       |
|         | C         | 45 (21.4)                     | 94 (19.2)                  | 1.144 (0.751–1.744), 0.531            |

* Adjusted for confounder variables: age and gender.

According to the results of our study, rs11556218 T>G, rs4778889 T>C, and rs4072111 C>T polymorphisms of *Il-16* gene are associated with patients’ susceptibility to chronic hepatitis B infection. As we showed in the results section rs4072111 and rs11556218 polymorphisms are in relationship with higher susceptibility of general population for development of chronic HBV and rs4778889 polymorphism which is associated with higher risk of chronic HBV among HBV infected individuals.

A recent published study on Chinese patients suffering from hepatitis C virus (HCV) disease revealed that there is an association between STAT6 SNPs and patients' susceptibility to sustained viral response. These outcomes suggest that STAT6 SNPs are prospective genetic biomarkers for HCV prognosis [23].

Li et al. reported that the genetic variations (SNPs) of *Il-16* are significantly related to chronic HBV related hepatocellular carcinoma (HCC). These results also showed that rs11556218 TG and GG genotypes of the *Il-16* gene contributed in patients’ susceptibility to chronic hepatitis B when using healthy subjects as controls [24].

In our previous study we have shown that there is a significant relationship between the micro-RNA binding site polymorphism of the *Il-16* gene and risk of colorectal cancer (CRC) [25]. Our previous study also suggested that rs11556218 T>G and rs4778889 T>C polymorphisms have influence on the altered risk of CRC [26].

In conclusion, HBV infected patients with anti-HBc Ab positive test who have had CC genotype rs4778889 are more susceptible to establish a chronic disease. We can also conclude that rs4072111 and rs11556218 polymorphisms are suitable susceptibility biomarkers for development of chronic HBV infection. Our results are in concordance with previous studies and we suggest that *Il-16* is related to hepatitis B infection and *Il-16* gene polymorphisms are considerable host genetic factors for patients’ susceptibility to chronic hepatitis B infection.

**Conflict of Interests**

The authors declare that they have no potential conflict of interests.

**Acknowledgments**

This project was supported by the Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors would like to thank the lab staff Seyedeh Mina Seyedi, Hanieh Mirtalebi, and Farahnaz Jabbarian for their kind assistance.

**References**

[1] B. Custer, S. D. Sullivan, T. K. Hazlet et al., “Global epidemiology of hepatitis B virus,” *Journal of Clinical Gastroenterology*, vol. 38, no. 10, supplement 3, pp. S158–S168, 2004.

[2] A. Wasley, D. Kruzon-Moran, W. Kuhnert et al., “The prevalence of hepatitis B virus infection in the united states in the era of vaccination,” *The Journal of Infectious Diseases*, vol. 202, no. 2, pp. 192–201, 2010.
[3] S. Amini, M. F. Mahmoodi, S. Andalibi, and A. Solati, "Seropidemiology of hepatitis B, Delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study," The Journal of Tropical Medicine and Hygiene, vol. 96, no. 5, pp. 277–287, 1993.

[4] J. Poorolajal and R. Majdzadeh, "Prevalence of chronic hepatitis B infection in Iran: a review article," Journal of Research in Medical Sciences, vol. 14, no. 4, pp. 249–258, 2009.

[5] W. W. Cruikshank, D. M. Center, N. Nisar et al., "Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 11, pp. 5109–5113, 1994.

[6] J. Richmond, M. Tuzova, W. Cruikshank, and D. Center, "Regulation of cellular processes by interleukin-16 in homeostasis and cancer," Journal of Cellular Physiology, vol. 229, no. 2, pp. 139–147, 2014.

[7] W. W. Cruikshank, D. M. Center, N. Nisar et al., "Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 11, pp. 5109–5113, 1994.

[8] C. Liu, J. Mills, K. Dixon et al., "IL-16 signaling specifically induces STAT6 activation through CD4," Cytokine, vol. 38, no. 3, pp. 145–150, 2007.

[9] S. J. Chapman and A. V. S. Hill, "Human genetic susceptibility to infectious disease," Nature Reviews Genetics, vol. 13, no. 3, pp. 175–188, 2012.

[10] Y. Kamatani, S. Wattanapokayakit, H. Ochi et al., "A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians," Nature Genetics, vol. 41, no. 5, pp. 591–595, 2009.

[11] A. Rauch, Z. Kutalik, P. Descombes et al., "Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study," Gastroenterology, vol. 138, no. 4, pp. 1338–1345, 2010.

[12] S. Urbani, C. Boni, B. Amadei et al., "Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection," Hepatology, vol. 41, no. 4, pp. 826–831, 2005.

[13] K. C. Wilson, D. M. Center, and W. W. Cruikshank, "The effect of interleukin-16 and its precursor on T lymphocyte activation and growth," Growth Factors, vol. 22, no. 2, pp. 97–104, 2004.

[14] J. Sambrook, Molecular Cloning: A Laboratory Manual, edited by J. Sambrook, D. W. Russell, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, 2001.

[15] L.-B. Gao, L. Rao, Y.-Y. Wang et al., "The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer," Carcinogenesis, vol. 30, no. 2, pp. 295–299, 2009.

[16] N. Bannert, K. Vollhardt, B. Asomuddinov et al., "PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits," Journal of Biological Chemistry, vol. 278, no. 43, pp. 42190–42199, 2003.

[17] E. A. Lynch, C. A. W. Heijens, N. F. Horst, D. M. Center, and W. W. Cruikshank, "Cutting edge: IL-16/CD4 preferentially induces TTh cell migration: requirement of CCR5," The Journal of Immunology, vol. 171, no. 10, pp. 4965–4968, 2003.

[18] K. Bowers, C. Pitcher, and M. Marsh, "CD4: a co-receptor in the immune response and HIV infection," The International Journal of Biochemistry and Cell Biology, vol. 29, no. 6, pp. 871–875, 1997.

[19] B. Jaruga, F. Hong, R. Sun, S. Radaeva, and B. Gao, "Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes," The Journal of Immunology, vol. 171, no. 6, pp. 3233–3246, 2003.

[20] A. Durán, A. Rodriguez, P. Martin et al., "Crosstalk between PKCζ and the IL4/Stat6 pathway during T-cell-mediated hepatitis," EMBO Journal, vol. 23, no. 23, pp. 4595–4605, 2004.

[21] T. Manigold and V. Racanelli, "T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies," The Lancet Infectious Diseases, vol. 7, no. 12, pp. 804–813, 2007.

[22] H. M. Diepolder, M.-C. Jung, E. Keller et al., "A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B," Clinical & Experimental Immunology, vol. 113, no. 2, pp. 244–251, 1998.

[23] Y. P. Lim, Y. A. Hsu, K. H. Tsai et al., "The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese," BMC Immunology, vol. 14, no. 1, article 21, 2013.

[24] S. Li, Y. Deng, Z.-P. Chen et al., "Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population," Infection, Genetics and Evolution, vol. 11, no. 8, pp. 2083–2088, 2011.

[25] P. Azimzadeh, S. Romani, S. R. Mohebbi et al., "Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population," Cancer Genetics, vol. 205, no. 10, pp. 501–507, 2012.

[26] P. Azimzadeh, S. Romani, S. R. Mohebbi et al., "Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer," Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 4, pp. 371–376, 2011.